Anika Therapeutics (NSDQ:ANIK) said today that it won CE Mark approval in the European Union for its Orthovisc-T injection. The Bedford, Mass.-based company’s treatment is indicated to relieve pain and restore function in tendons affected by tennis elbow, or chronic lateral epicondylosis.
The sodium hyaluronate injection promotes tendon gliding and repair at the site of the damaged tissue, according to Anika.
“We’re excited to announce the timely European approval of Orthovisc-T for the treatment of pain associated with one of the most common overuse injuries to connective tissues, the condition commonly described as tennis elbow,” president & CEO Charles Sherwood said in prepared remarks. “The availability of Orthovisc-T not only promises to help millions of people in Europe find relief from this painful condition, it also expands our global foothold in orthopedic medicine and provides real-world clinical experience to inform our path towards regulatory submission in the U.S.”
“Degenerative overuse injuries to tendons are a leading cause of pain and restricted activity, and, until now, treatments were limited to oral medications, physical and/or occupational therapy, and corticosteroid injections,” hand and upper extremity specialist at Sports Medicine North Dr. Peter Prokopis added. “Orthovisc-T is a natural and effective solution that not only relieves pain, but also addresses the source of pain and discomfort and promotes natural resolution of the symptoms and ultimate recovery.”
In March, Anika won CE Mark approval for its Cingal combined viscosupplement with cross-linked sodium hyaluronate and triamcinolone hexacetonide for osteoarthritis-related knee pain.
